Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Kidney Health Initiative Resource Report Resource Website |
Kidney Health Initiative (RRID:SCR_003869) | KHI | data or information resource, consortium, portal, organization portal | Consortium that brings together the kidney community (patient advocacy groups, industry, government agencies, and professional organizations) to overcome existing challenges, including regulatory and nonregulatory barriers, and optimize the development and safety of products that impact kidney health including drugs, devices, biologics, and food products. The goals of the consortium are to: * Facilitate dialogue and research that informs regulatory processes with regard to the kidney health of patients being treated for kidney-related as well as other diseases. * Assess current medical therapies and diagnostics to identify areas in need of greater innovation and/or better defined regulatory pathways. * Develop innovative and efficient trial designs appropriate to answer the most important questions related to kidney health. * Establish expert consensus around common terminology and key definitions related to kidney health. * Develop approaches to the systematic collection of retrospective or prospective data, such as registries and/or global databases, and establishment of data standards. * Coordinate think tanks, public forums, educational exchanges, and other events to promote discussion and updates on topics in kidney health pertaining to drug, device, biologics, and food product development and evaluation. * Create transparent infrastructure and processes that facilitate collaboration and communication among the greater nephrology community and the FDA, including: * Seek input from all stakeholders (including nephrologists and other health professionals, patient groups, industry, the National Institutes of Health, the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, and other federal agencies). * Leverage previously conducted and ongoing clinical studies, research infrastructure, and databases. * Create an open and efficient mechanism for encouraging and objectively evaluating potential projects submitted to KHI. * Involve consortium members in the selection and execution of projects. * Establish systems to optimize post-market surveillance of products that affect kidney health, either intentionally or via adverse drug reactions. * Author journal articles and white papers regarding key issues, describing opportunities and challenges and proposing solutions, as well as promoting execution of these solutions. | device development, drug development, tool development, basic research, drug, device, biologics, food product, kidney, data standard, nephrology, safety, innovation, public health |
is listed by: Consortia-pedia is related to: AbbVie is related to: American Association of Kidney Patients is related to: American College of Clinical Pharmacy is related to: American Nephrology Nurses Association is related to: American Society for Apheresis is related to: American Society of Diagnostic and Interventional Nephrology is related to: ASN - American Society of Nephrology is related to: American Society of Pediatric Nephrology is related to: American Society of Transplantation is related to: Anthera Pharmaceuticals is related to: Arbor Research Collaborative for Health is related to: Association for the Advancement of Medical Instrumentation is related to: Baxter is related to: C. R. Bard is related to: ChemoCentryx is related to: ClinMet is related to: University of Oxford; Oxford; United Kingdom is related to: DaVita is related to: Dialysis Patient Citizens is related to: Duke University School of Medicine; North Carolina; USA is related to: ERA-EDTA is related to: FAST BioMedical is related to: Shire is related to: Home Dialyzors United is related to: Hospira is related to: All India Institute of Medical Sciences; New Delhi; India is related to: Juvenile Diabetes Research Foundation is related to: Karolinska Institute; Stockholm; Sweden is related to: University of Washington; Seattle; USA is related to: Mallinckrodt Pharmaceuticals is related to: MediBeacon is related to: Medtronic is related to: National Kidney Foundation is related to: National Renal Administrators Association is related to: NephCure Kidney International is related to: Nephrology Nursing Certification Commission is related to: Nephropath is related to: NxStage Medical is related to: OPKO is related to: Otsuka America Pharmaceutical Inc. is related to: Pfizer Animal Genetics is related to: PKD Foundation is related to: Proteon Therapeutics is related to: Puracath Medical is related to: Quintiles is related to: Reata Pharmaceuticals is related to: Relypsa is related to: Renal Physicians Association is related to: Renal Support Network is related to: Rockwell Medical is related to: St. Marianna University School of Medicine; Kawasaki; Japan is related to: Binding Site is related to: George Institute for Global Health is related to: Thrasos Therapeutics is related to: Vascular Access Society is related to: Vascular Access Society of the Americas is related to: Vascular Therapies is related to: Vasculitis Foundation is related to: W. L. Gore and Associates is related to: U.S. Food and Drug Administration has parent organization: ASN - American Society of Nephrology has parent organization: U.S. Food and Drug Administration has parent organization: Agency for Healthcare Research and Quality has parent organization: Centers for Medicare and Medicaid Services has parent organization: National Institutes of Health |
U.S. Food and Drug Administration ; Membership dues |
nlx_158194 | SCR_003869 | Kidney Health Initiative (KHI) | 2026-08-11 09:40:49 | 0 | |||||||
|
Polycystic Kidney Disease Outcomes Consortium Resource Report Resource Website |
Polycystic Kidney Disease Outcomes Consortium (RRID:SCR_003674) | PKDOC | data or information resource, consortium, portal, organization portal | Consortium to develop evidence supporting the use of imaging Total Kidney Volume (TKV) as a prognostic biomarker that predicts the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to select patients likely to respond to therapy into clinical trials. It aims to replace the currently used measurement of glomerular filtration rate (GFR). Scientists will use the data collected to develop a disease progression model that will evaluate the relationship between TKV and the known complications of ADPKD, including rate of loss of kidney function, hypertension, gross hematuria, kidney stones, urinary tract infections, development of end-stage renal disease, and mortality. These analyses will be used to support the regulatory qualification of TKV as an accepted measure for assessing the progression of ADPKD in clinical trials in which new therapies are tested. PKDOC has the following goals: # Develop standard clinical data elements and definitions that are specific to ADPKD # Create a database of aggregated data from existing multiple, longitudinal, and well-characterized research registries maintained over decades by the leading institutions in ADPKD clinical investigation # Advance and harmonize the missions of regulatory agencies by creating tools that help with the evaluation of new pharmaceutical compounds # Develop a quantitative disease progression model to examine the linkage between TKV and disease outcomes | consortium, drug, imaging, total kidney volume, biomarker, rate, disease progression, imaging biomarker, drug development, kidney volume, kidney, clinical, common data element, therapeutic, clinical trial, standard specification, database |
is listed by: Consortia-pedia has parent organization: Critical Path Institute; Arizona; USA |
PKD Foundation ; Philanthropic donations ; U.S. Food and Drug Administration |
nlx_157909 | SCR_003674 | PKD Outcomes Consortium, PKD Consortium, Polycystic Kidney Disease (PKD) Outcomes Consortium | 2026-08-11 09:40:52 | 0 | |||||||
|
Rockwell Medical Resource Report Resource Website |
Rockwell Medical (RRID:SCR_004050) | Rockwell, RMTI | data or information resource, portal, organization portal, commercial organization | A fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency anemia, secondary hyperparathyroidism and hemodialysis. | pharmaceutical, biopharmaceutical, dialysis, hemodialysis, drug | is related to: Kidney Health Initiative | Kidney disease, Iron deficiency anemia, End-stage renal disease, Iron deficiency, Chronic kidney disease, Secondary hyperparathyroidism | nlx_158480 | SCR_004050 | Rockwell Medical Inc., Rockwell Medical Technologies Inc. | 2026-08-11 09:40:54 | 0 | |||||||
|
ILSI HESI Drug-induced Nephrotoxicity Biomarkers Resource Report Resource Website |
ILSI HESI Drug-induced Nephrotoxicity Biomarkers (RRID:SCR_003716) | HESI Nephrotoxicity Biomarkers | data or information resource, standard specification, narrative resource | Urinary kidney biomarkers, Clusterin and Renal Papillary Antigen-1 (RPA-1), that sponsors may use to determine more conservative NOAELs for estimating starting doses in the initial human clinical trial of a drug that displays nonclinical nephrotoxicity as determined by histopathology. When tested with a limited number of nephrotoxic compounds, the Receiver Operating Characteristic (ROC) analyses showed that urinary clusterin and renal papillary antigen-1 (RPA-1) have better sensitivity and specificity than BUN and creatinine for the detection of specific kidney pathologies in male rats. Clusterin and RPA-1 provide additional and complementary information to BUN, serum creatinine (sCr), and histopathology for the detection of acute drug-induced nephrotoxicity in safety assessment studies. | biomarker, drug development, drug, urinary, urinary biomarker, gold standard, clusterin, renal papillary antigen, kidney, gold standard |
is recommended by: U.S. Food and Drug Administration is related to: Health and Environmental Sciences Institute (HESI) has parent organization: Drug Development Tools Qualification Programs |
Nephrotoxicity, Drug-induced nephrotoxicity | Public | nlx_157892 | SCR_003716 | HESI Drug-induced Nephrotoxicity Biomarkers, ILSI / HESI Nephrotoxicity Working Group Drug-induced Nephrotoxicity Biomarkers, International Life Sciences Institute / Health and Environmental Sciences Institute Nephrotoxicity Working Group Drug-induced Nephrotoxicity Biomarkers | 2026-08-11 09:40:50 | 0 | ||||||
|
Renin Angiotensin System Study Resource Report Resource Website 1+ mentions |
Renin Angiotensin System Study (RRID:SCR_013385) | RASS/B-RASS, RASS | clinical trial, resource | Randomized, multicenter, double-blind study to determine if renin angiotensin medications, either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor), can prevent or delay the onset of diabetic kidney disease in patients with type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria. Two hundred eight five patients ages 16-61 with 2-20 yrs of Type 1 Diabetes Mellitus and no renal functional abnormalities were randomized into a parallel, double-blind, placebo-controlled study involving 3 groups (95 patients/group). Each group received an angiotensin-converting enzyme inhibitor (ACEI) (enalapril), or an angiotensin II receptor blocker (Losartan), or placebo. All patients had their usual Diabetes Mellitus (DM) management. Baseline studies included measures of glomerular filtration rate (GFR), urinary albumin excretion rate (UAE), blood pressure (BP), and a percutaneous renal biopsy. Patients were followed by quarterly measures of BP, HbA1C, UAE, and drug compliance. There were annual measures of GFR and a repeat renal biopsy after 5 yrs in the study. The main endpoint is kidney structural changes over time, especially mesangial fractional volume (v(Mes/glom)). Secondary endpoints will be other DN structural measures and measures of kidney function (UAE, GFR). These studies will determine whether rennin angiotensin system blockage in the early stages of DN can prevent the early kidney structural changes in this important disorder. Ancillary studies will evaluate the effects of treatment group on the development and progression of diabetic retinopathy and will develop predictors of study participants'''' compliance. Baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients were obtained. | enalapril, drug, losartan, angiotensin, medication, kidney, intervention, clinical, adolescent, adult human, renal biopsy, renin-angiotensin system, diabetic nephropathy, kidney, placebo, glomerular filtration rate, urinary albumin excretion rate, blood pressure |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Minnesota Twin Cities; Minnesota; USA |
Type 1 diabetes, Diabetic kidney disease, Retinopathy, Nephropathy, Diabetes | NIDDK | PMID:19571282 | nlx_152849 | SCR_013385 | Renin Angiotensin System Blockage-DN (RASS), Renin Angiotensin System Study (RASS/B-RASS) | 2026-08-11 09:42:42 | 1 | |||||
|
ClinMet Resource Report Resource Website 1+ mentions |
ClinMet (RRID:SCR_003979) | ClinMet | commercial organization | THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021.Organization that uses metabolomics to provide pharmaceutical companies with clinically relevant and practical insight into drug response and safety for renal and cardiovascular diseases, obesity and diabetes. Their combination of skills to achieve exhaustive understanding of a disease along with detailed clinical insights, signature panel of urine-based metabolomic biomarkers, proprietary metabolomics and computational expertise will accelerate the speed and success rate of drug development. ClinMet helps drug developers to efficiently transform promising compounds into safe and effective medicines. Their efficacy and toxicity indices enable pharmaceutical companies to make better clinical trial-related decisions and provide an increased understanding of a drug''s mechanism of action. | metabolomics, drug, mechanism of action, clinical, clinical trial, drug efficacy, toxicity, drug discovery, drug development, kidney, safety, efficacy, medicine | is related to: Kidney Health Initiative | nlx_158384 | SCR_003979 | Clinical Metabolomics Inc, Clinical Metabolomics Inc. | 2026-08-08 11:58:11 | 1 | ||||||||
|
Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus Resource Report Resource Website |
Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus (RRID:SCR_003731) | AMP Autoimmune, AMP RA/SLE | data or information resource, consortium, portal, organization portal | The autoimmune disease arm of the Accelerating Medicine Partnership (AMP), which aims to identify and validate the most promising biological targets of disease for new diagnostic and drug development, that is focused on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). They seek to identify shared common flaws in inflammation, particularly those that are shared with a larger number of autoimmune disorders which can cause severe disability, greatly affect quality of life, and are associated with an increased risk of death. This project aims to reveal biomarkers and biological targets for drug development, matching existing drugs to patients with specific molecular profiles who are most likely to benefit. The research plan proposes a 5 year process. Year one will include startup activities such as validation of tissue acquisition processes and analytic technologies, and the development of operating procedures. The second year will focus on identification of disease specific pathways by comparing data from patients and healthy individuals. Years 3-5 will expand the scale to include comparisons of different subsets of patients with RA or lupus to allow molecularly based patient stratification for precise treatment. The final 12 months (2019) will also include preliminary target validation. The data will be made publicly available through an internet-based information portal. | drug, drug development, biomarker, data sharing, consortium, gene expression, signaling, tissue, organ, synovium, kidney, skin, blood cell, inflammation |
is listed by: Consortia-pedia is related to: Accelerating Medicines Partnership - Alzheimers is related to: Accelerating Medicines Partnership - Alzheimers is related to: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) has parent organization: Foundation for the National Institutes of Health has parent organization: Accelerating Medicines Partnership |
NIH ; Industry partners |
nlx_157975 | SCR_003731 | Accelerating Medicines Partnership - Autoimmune, AMP Autoimmune Diseases of Rheumatoid Arthritis and Lupus, AMP RA/SLE Program, Accelerating Medicines Partnership - Autoimmune Diseases, Accelerating Medicines Partnership - Arthritis, AMP Rheumatoid arthritis and lupus, Accelerating Medicines Partnership - Autoimmune Diseases of Rheumatoid Arthritis and Lupus | 2026-08-11 09:40:53 | 0 | |||||||
|
Predictive Safety Testing Consortium Resource Report Resource Website |
Predictive Safety Testing Consortium (RRID:SCR_003727) | PSTC | data or information resource, consortium, portal, organization portal | A public-private partnership to identify new and improved translational safety testing methods for use in nonclinical and clinical studies and submit them for formal regulatory qualification by the FDA (Food and Drug Administration), EMA (European Medicines Agency), and PMDA (Japanese Pharmaceutical and Medical Devices Agency). The current 19 corporate members of the consortium share internal experience with nonclinical and clinical safety biomarkers in six working groups: cardiac hypertrophy, nephrotoxicity, hepatotoxicity, skeletal myopathy, testicular toxicity, and vascular injury. The ultimate goal of the consortium is to improve the current approach to drug safety testing and offer assurance to the drug developers that these approaches will be accepted by the regulatory authorities in their drug development programs. Through PSTC, members are able to share their expertise, resources, data, and internally developed approaches in a neutral, precompetitive, confidential environment. There are more than 250 participating scientists and C-Path serves as the trusted third party, leading the collaborative process by collecting and summarizing the data, and leading the interactions with global health authorities. | drug, consortium, safety testing, safety, drug safety, clinical, nonclinical, biomarker, kidney, testicular, liver, skeletal muscle, vascular, drug development, biomarker assay |
is listed by: Consortia-pedia is related to: European Medicines Agency is related to: Pharmaceuticals and Medical Devices Agency has parent organization: Critical Path Institute; Arizona; USA is parent organization of: PSTC Nephrotoxicity Biomarkers |
annual dues ; in-kind contributions ; U.S. Food and Drug Administration |
nlx_157912 | SCR_003727 | 2026-08-11 09:40:50 | 0 | ||||||||
|
PSTC Nephrotoxicity Biomarkers Resource Report Resource Website |
PSTC Nephrotoxicity Biomarkers (RRID:SCR_003709) | PSTC Nephrotoxicity Biomarkers | data or information resource, standard specification, narrative resource | Urinary kidney biomarkers (KIM-1, albumin, total protein, 2-microglobulin, cystatin C, clusterin and trefoil factor-3) that are considered acceptable biomarkers for the detection of acute drug-induced nephrotoxicity in rats and can be included along with traditional clinical chemistry markers and histopathology in toxicology studies. These biomarkers may be used voluntarily as additional evidence of nephrotoxicity in nonclinical safety assessment studies to complement the standard data (BUN and sCr). In ROC analyses, some of these biomarkers showed better sensitivity and specificity than BUN and sCr relative to histopathological alterations considered to be the gold standard when tested with a limited number of nephrotoxicant and control compounds. | biomarker, drug development, drug, urinary, urinary biomarker, gold standard, kim-1, albumin, total protein, beta2-microglobulin, cystatin c, clusterin, trefoil factor-3, kidney, nonclinical |
is recommended by: U.S. Food and Drug Administration has parent organization: Drug Development Tools Qualification Programs has parent organization: Predictive Safety Testing Consortium |
Nephrotoxicity, Drug-induced nephrotoxicity | Public | nlx_157890 | SCR_003709 | Predictive Safety and Testing Consortium Drug-induced Nephrotoxicity Biomarkers, PSTC NWG Drug-induced Nephrotoxicity Biomarkers | 2026-08-11 09:40:49 | 0 | ||||||
|
Coalition For Accelerating Standards and Therapies Resource Report Resource Website 1+ mentions |
Coalition For Accelerating Standards and Therapies (RRID:SCR_000206) | CFAST | data or information resource, portal | Consortium establishing data standards, tools and methods for conducting research in therapeutic areas important to public health including Alzheimer's disease, Parkinson's disease, multiple sclerosis, polycystic kidney disease, and tuberculosis.CDISC and C-Path have agreed to discontinue using separate CFAST brand, but they both remain committed to this mission and continue to partner to develop and publish therapeutic area data standards. | CDISC, C-Path, drug, clinical trial, data element, data sharing, clinical, virology |
is listed by: Consortia-pedia has parent organization: Critical Path Institute; Arizona; USA |
FDA 1U01FD003865-01 | nlx_157879 | SCR_000206 | Coalition For Accelerating Standards and Therapies (CFAST) | 2026-08-10 09:31:06 | 1 | |||||||
|
Proteon Therapeutics Resource Report Resource Website 1+ mentions |
Proteon Therapeutics (RRID:SCR_004037) | Proteon | commercial organization | A biopharmaceutical company developing pharmaceuticals for patients with renal and vascular diseases. Their ongoing Phase 3 clinical trial is evaluating whether a single treatment of PRT-201 can reduce vascular access failure, one of the most serious problems experienced by patients with chronic kidney disease (CKD) undergoing hemodialysis. PRT-201 is an investigational drug that may inhibit neointimal hyperplasia, the growth of tissue inside blood vessels that can result in vessel narrowing and reduced blood flow. PRT-201 has received fast track and orphan drug designations for hemodialysis vascular access indications.In September 2019, Proteon Therapeutics merged with ArTara Therapeutics. | biopharmaceutical, pharmaceutical, hemodialysis, prt-201, drug |
is related to: Kidney Health Initiative is related to: Protara Therapeutics |
Kidney disease, Vascular disease, Chronic kidney disease, Neointimal hyperplasia, Peripheral arterial disease | nlx_158465 | SCR_004037 | Proteon Therapeutics Inc. | 2026-08-08 11:58:09 | 1 | |||||||
|
Drug-Induced Liver Injury Network Resource Report Resource Website 1+ mentions |
Drug-Induced Liver Injury Network (RRID:SCR_001524) | DILIN | biomaterial supply resource, material resource | Prospective and retrospective registry of well-characterized cases of drug-induced liver disease. The goals of Network include the development of standardized procedures to identify and fully characterize bona fide cases of drug- and complementary and alternative medicines (CAM)-induced liver injury, and to conduct controlled, clinical studies that will include extensive collection of data, serum, DNA, and tissue specimens. Cases of liver injury due to herbal medications are also included. The network will also develop terminology and standardized definitions for DILI, and to develop causality assessment instruments that are sensitive, specific, and reproducible. DILIN is funded by a cooperative agreement and includes five clinical centers and a central data coordinating center. The research goals of DILIN are to: * Create a registry of carefully documented DILI cases * Identify clinical, immunological, and environmental risk factors for drug- and CAM-mediated hepatotoxicity * Create a bank of biological specimens consisting of DNA, plasma, and immortalized lymphocytes to facilitate detailed genetic analyses * Characterize the natural history of drug- and CAM-induced DILI for at least six months following enrollment * Develop the capability to recontact these individuals over an extended period of time so that additional studies exploring DILI mechanisms can be performed Two studies are being initiated by the network. In the Retrospective Study, the implicated drugs are restricted to isoniazid, phenytoin, combination clavulanic acid/amoxicillin, and valproic acid (Depakote), Nitrofurantoin, Trimethoprim-sulfamethoxazole, Minocycline, and Quinolone antibiotics. These drugs were chosen because they are frequently administered to patients not receiving other hepatotoxic drugs, making it easier to establish causality. Patients must be alive, and the date of onset of the DILI episode must be on or after January 1, 1994. In the Prospective Study, all incident cases of drug- and CAM-induced liver injury are being considered. Initial presentation to a healthcare professional must be within the previous six months. A detailed medication history of the implicated DILI drug together with all prescription, OTC, and herbal medications is being recorded. Liver and serological tests are being performed to characterize the injury and to exclude competing causes of liver injury. A blood sample is also being drawn for plasma storage and DNA isolation. These cases will be followed longitudinally to characterize the long-term effects of the DILI episode. For both studies, documented, clinically significant DILI must be recorded in the patient's medical charts so that a causal determination can be made. Patients will be excluded if they are unwilling or unable to provide a blood sample or participate in the genetics component. Children under two years of age at the time of enrollment are excluded due to blood-volume requirements. If you have patients who are eligible to participate in either study, please contact one the DILIN clinical sites. As a general policy, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigator-initiated research project applications for ancillary studies to ongoing, large-scale clinical trials, epidemiological studies, and disease databases supported by the Institute. These studies are focused on a wide range of diseases and conditions including diabetes, obesity, acute and chronic liver disease, chronic kidney disease, and benign prostatic hyperplasia, among others. | prescription drug, over-the-counter drug, alternative medicine, herbal product, supplement, serum, dna, tissue, blood, immortalized lymphocyte, drug, medication, quinolone antibiotic, isoniazid, phenytoin, clavulanic acid, amoxicillin, valproic acid, depakote, nitrofurantoin, trimethoprim-sulfamethoxazole, minocycline, diagnosis, hepatotoxicity, risk factor, genetic analysis |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers has parent organization: Duke University; North Carolina; USA |
Liver injury, Hepatic injury, Drug-induced liver disease | NIDDK | Qualified investigators, Account required | nlx_152822 | https://dilin.dcri.duke.edu/ | SCR_001524 | 2026-08-11 09:40:21 | 6 | |||||
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | service resource, resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-08-11 09:41:28 | 0 | |||||
|
Type 1 Diabetes - Rapid Access to Intervention Development Resource Report Resource Website |
Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR_000203) | T1D-RAID | service resource, resource | NOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDKstaff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDKand NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: * Definition or optimization of dose and schedule for in vivo activity * Development of pharmacology assays * Conduct of pharmacology studies with a pre-determined assay * Acquisition of bulk substance (GMP and non-GMP) * Scale-up production from lab-scale to clinical-trials lot scale * Development of suitable formulations * Development of analytical methods for bulk substances * Production of dosage forms * Stability assurance of dosage forms * Range-finding initial toxicology * IND-directed toxicology, with correlative pharmacology and histopathology * Planning of clinical trials * Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic * IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials. | therapeutic, drug, drug development, pharmacogenomics |
is listed by: NIDDK Information Network (dkNET) is related to: Type 1 Diabetes Preclinical Testing Program has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NCI ; NIDDK |
nlx_152742 | SCR_000203 | Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID) | 2026-08-11 09:40:07 | 0 | ||||||
|
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia Resource Report Resource Website |
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia (RRID:SCR_007126) | MIST for BPH | clinical trial, resource | Randomized clinical trial to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. The study has been terminated. (Inability to recruit required sample size.) | transurethral microwave thermotherapy, transurethral needle ablation, therapy, drug, finasteride, alfuzosin, treatment, clinical, intervention, male, middle adult human, late adult human, prostate |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Benign Prostatic Hyperplasia | NIDDK | nlx_152844 | SCR_007126 | Minimally Invasive Surgical Therapies (MIST) Treatment Consortium for Benign Prostatic Hyperplasia (BPH), Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia | 2026-08-11 09:41:30 | 0 | ||||||
|
Mallinckrodt Pharmaceuticals Resource Report Resource Website 1+ mentions |
Mallinckrodt Pharmaceuticals (RRID:SCR_003986) | Mallinckrodt | commercial organization | An independent global pharmaceutical company that produces specialty pharmaceutical products including generic drugs and imaging agents. They manufacture and distribute products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals. They are the largest U.S. supplier, by prescription, of opioid pain medications and the largest U.S. supplier of the medical isotope technetium-99m. The company is among the top 10 generic pharmaceuticals manufacturers in the United States. The company is also the largest producer of bulk acetaminophen. Mallinckrodt also produces cocaine derived from the Coca-Cola coca leaves, extracted by the Stepan Company. (Adapted from Wikipedia, 10/2014) | pharmaceutical, drug, analgesic, neurology, rheumatology, nephrology, pulmonology, narcotic, acetaminophen, stearate, phosphate, peptide, medical imaging, imaging, contrast agent, delivery system, radiopharmaceutical, questcor pharmaceuticals inc., questcor pharmaceuticals, questcor | is related to: Kidney Health Initiative | Acute pain, Chronic pain, Brain disease, Autoimmune diease, Inflammatory disease | Wikidata: Q30273990, grid.482334.a, nlx_158397, ISNI: 0000 0004 4652 5312 | https://ror.org/00467td76 | SCR_003986 | Mallinckrodt plc | 2026-08-08 11:58:14 | 2 | ||||||
|
Shire Resource Report Resource Website 10+ mentions |
Shire (RRID:SCR_003984) | Shire | commercial organization | Global specialty biopharmaceutical company that focuses on developing treatments for conditions where the impact of their medicines can make an immediate and tangible difference for patients. They provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. This might be a therapy to treat an extremely rare and life-threatening disease like Hunter syndrome or Fabry disease; or a medicine for a specialist condition like ADHD or ulcerative colitis which if not treated effectively, can dramatically affect the lives of the patient and their whole family.Shire was acquired by Takeda Pharmaceutical company on January 8, 2019. | pharmaceutical, fibrotech therapeutics pty ltd., fibrotech therapeutics pty ltd, fibrotech therapeutics, fibrotech, medicine, drug |
is related to: Kidney Health Initiative is related to: Takeda Pharmaceutical Company Limited |
nlx_158391 | SCR_003984 | Takeda Pharmaceutical, Shire plc, Fibrotech Therapeutics | 2026-08-08 11:58:08 | 15 | ||||||||
|
ChemoCentryx Resource Report Resource Website 10+ mentions |
ChemoCentryx (RRID:SCR_003976) | commercial organization | A biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Each drug candidate is a small molecule designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biopharmaceutical, oral administration, medicine, small molecule, chemokine, chemo-attractant receptor, clinical, drug, oral drug | is related to: Kidney Health Initiative | Autoimmune disease, Inflammatory disorder, Cancer | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158383, grid.452218.8, ISNI: 0000 0004 0408 7502 | https://ror.org/04gp12571 | SCR_003976 | ChemoCentryx Inc, ChemoCentryx Inc. | 2026-08-08 11:58:14 | 43 | ||||||
|
Anthera Pharmaceuticals Resource Report Resource Website |
Anthera Pharmaceuticals (RRID:SCR_003971) | Anthera | commercial organization | Biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. | pharmaceutical, biopharmaceutical, drug, medicine | is related to: Kidney Health Initiative | nlx_158378, grid.476018.c, ISNI: 0000 0004 6016 674X, Wikidata: Q4771754 | https://ror.org/04pa38t98 | http://www.anthera.com/ | SCR_003971 | Anthera Pharmaceuticals Inc. | 2026-08-08 11:58:08 | 0 | ||||||
|
Quintiles Resource Report Resource Website 1+ mentions |
Quintiles (RRID:SCR_004039) | Quintiles | commercial organization | Contract research organization, clinical trial services, and pharmaceutical consulting service company. Now IQVIA after merger of Quintiles and IMS Health, Inc. | contract research organization, pharmaceutical consulting, pharmaceutical, clinical trial service, clinical trial, drug, biopharmaceutical |
is related to: Kidney Health Initiative is related to: IQVIA is parent organization of: Q Squared Solutions Expression Analysis |
nlx_158467 | SCR_004039 | Quintiles Transnational, Quintiles Global Clinical Research Organization, Quintiles Inc. | 2026-08-08 11:58:15 | 9 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant U24DK097771.
Email: info_at_ dknet.org
